Interestingly, the same combination evaluated in patients with advanced melanoma showed no difference in terms of response according to ATM or PD-L1 status; patients with HRD tumours seemed to benefit more from this combination, although no significant difference in PFS could be observed (hazard ratio, 0.17 [95% CI, 0.02–1.43]). This evidence concerns the gene CD274 and melanoma.